Unknown

Dataset Information

0

Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.


ABSTRACT: Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is a novel and highly pathogenic coronavirus and is the causative agent of the coronavirus disease 2019 (COVID-19). The high morbidity and mortality associated with COVID-19 and the lack of an approved drug or vaccine for SARS-CoV-2 underscores the urgent need for developing effective antiviral therapies. Therapeutics that target essential viral proteins are effective at controlling virus replication and spread. Coronavirus Spike glycoproteins mediate viral entry and fusion with the host cell, and thus are essential for viral replication. To enter host cells, the Spike proteins of SARS-CoV-2 and related coronavirus, SARS-CoV, bind the host angiotensin-converting enzyme 2 (ACE2) receptor through their receptor binding domains (RBDs). Here, we rationally designed a panel of ACE2-derived peptides based on the RBD-ACE2 binding interfaces of SARS-CoV-2 and SARS-CoV. Using SARS-CoV-2 and SARS-CoV Spike-pseudotyped viruses, we found that a subset of peptides inhibits Spike-mediated infection with IC50 values in the low millimolar range. We identified two peptides that bound Spike RBD in affinity precipitation assays and inhibited infection with genuine SARS-CoV-2. Moreover, these peptides inhibited the replication of a common cold causing coronavirus, which also uses ACE2 as its entry receptor. Results from the infection experiments and modeling of the peptides with Spike RBD identified a 6-amino-acid (Glu37-Gln42) ACE2 motif that is important for SARS-CoV-2 inhibition. Our work demonstrates the feasibility of inhibiting SARS-CoV-2 with peptide-based inhibitors. These findings will allow for the successful development of engineered peptides and peptidomimetic-based compounds for the treatment of COVID-19.

SUBMITTER: Larue RC 

PROVIDER: S-EPMC7784661 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.

Larue Ross C RC   Xing Enming E   Kenney Adam D AD   Zhang Yuexiu Y   Tuazon Jasmine A JA   Li Jianrong J   Yount Jacob S JS   Li Pui-Kai PK   Sharma Amit A  

Bioconjugate chemistry 20201224 1


Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is a novel and highly pathogenic coronavirus and is the causative agent of the coronavirus disease 2019 (COVID-19). The high morbidity and mortality associated with COVID-19 and the lack of an approved drug or vaccine for SARS-CoV-2 underscores the urgent need for developing effective antiviral therapies. Therapeutics that target essential viral proteins are effective at controlling virus replication and spread. Coronavirus Spike glycopr  ...[more]

Similar Datasets

| S-EPMC8239575 | biostudies-literature
| S-EPMC8584250 | biostudies-literature
| S-EPMC7931628 | biostudies-literature
| S-EPMC9110306 | biostudies-literature
| S-EPMC10724569 | biostudies-literature
| S-EPMC7168710 | biostudies-literature
| S-EPMC8898741 | biostudies-literature
| S-EPMC8786148 | biostudies-literature
| S-EPMC7811929 | biostudies-literature
| S-EPMC10179272 | biostudies-literature